A novel strategy for the generation of angiostatic kringle regions from a precursor derived from plasminogen

Gene Therapy

Volumn 9, Issue 23, 2002, Pages 1600-1606

  Schmitz, V ^a,b   Wang, L ^a   Barajas, M ^a   Peng, D ^a   Prieto, J ^a   Qian, C ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Angiogenesis; Angiostatin; Cancer; Endoprotease furin; Gene therapy

Indexed keywords

ADENOVIRUS VECTOR; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; FURIN; INTERLEUKIN 12; MATRIGEL; PLASMINOGEN; PROTEIN PRECURSOR; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CELL INFILTRATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENDOTHELIUM CELL; GENE EXPRESSION; GENE MUTATION; KRINGLE DOMAIN; LEWIS CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SUPERNATANT; UMBILICAL VEIN;

ADENOVIRIDAE; AMINO ACID SEQUENCE; ANGIOSTATINS; ANIMALS; BASE SEQUENCE; GENE THERAPY; GENETIC VECTORS; HUMANS; KRINGLES; LIVER NEOPLASMS, EXPERIMENTAL; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; MICE, NUDE; MOLECULAR SEQUENCE DATA; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PLASMINOGEN; TUMOR CELLS, CULTURED;

ADENOVIRIDAE; ANIMALIA;

EID: 0036893754     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301805     Document Type: Review

References (29)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
2. Gasparini G. the rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs 1999; 58: 17-38.
3. Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000; 52: 237-268.
4. Brower V. Tumor angiogenesis - new drugs on the block. Nat Biotechnol 1999; 17: 963-968.
5. O'Reilly MS et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-328.
6. Dong Z, Kumar R, Yang X, Fidler IJ. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 1997; 88: 801-810.
7. Gately S et al. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res 1996; 56: 4887-4890.
8. Cao Y et al. Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells. J Biol Chem 1996; 271: 29461-29467.
9. Cao Y et al. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem 1997; 272: 22924-22928.
10. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2: 689-692.
11. Sim BK et al. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res 1997; 57: 1329-1334.
12. Lannutti BJ et al. Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo. Cancer Res 1997; 57: 5277-5280.
13. Tanaka T, Cao Y, Folkman J, Fine HA. Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA. Cancer Res 1998; 58: 3362-3369.
14. Griscelli F et al. Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci USA 1998; 95: 6367-6372.
15. Indraccolo S et al. Effects of angiostatin gene transfer on functional properties and in vivo growth of Kaposi's sarcoma cells. Cancer Res 2001; 61: 5441-5446.
16. Kuo CJ et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci USA 2001; 98: 4605-4610.
17. Molloy SS, Anderson ED, Jean F, Thomas G. Bi-cycling the furin pathway: from TGN localization to pathogen activation and embryogenesis. Trends Cell Biol 1999; 9: 28-35.
18. Nakayama K. Furin: a mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins. Biochem J 1997; 327: 625-635.
19. Gros L et al. Insulin production by engineered muscle cells. Hum Gene Ther 1999; 10: 1207-1217.
20. Muzzin P, Eisensmith RC, Copeland KC, Woo SL. Hepatic insulin gene expression as treatment for type 1 diabetes mellitus in rats. Mol Endocrinol 1997; 11: 833-837.
21. Gaken J et al. Fusagene vectors: a novel strategy for the expression of multiple genes from a single cistron. Gene Therapy 2000; 7: 1979-1985.
22. Groskreutz DJ, Sliwkowski MX, Gorman CM. Genetically engineered proinsulin constitutively processed and secreted as mature, active insulin. J Biol Chem 1994; 269: 6241-6245.
23. Griscelli F et al. Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model. Proc Natl Acad Sci USA 2000; 97: 6698-6703.
24. Yao L et al. Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12. Blood 2000; 96: 1900-1905.
25. Gyorffy S et al. Combined treatment of a murine breast cancer model with type 5 adenovirus vectors expressing murine angiostatin and IL-12: a role for combined anti-angiogenesis and immunotherapy. J Immunol 2001; 166: 6212-6217.
26. Qian C, Bilbao R, Bruna O, Prieto J. Induction of sensitivity to ganciclovir in human hepatocellular carcinoma cells by adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase. Hepatology 1995; 22: 118-123.
27. Yao L et al. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood 1999; 93: 1612-1621.
28. Mishima K et al. A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. Proc Natl Acad Sci USA 2000; 97: 8484-8489.
29. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8.